Monograph Details
|
|
Endocrine System
> Diabetes
|
|
LEVEMIR |
| Manufacturer |
|
Novo Nordisk |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Insulin detemir [rDNA origin] 100 Units/mL; SC inj; contains m-cresol. |
| Indications |
|
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed. |
| Adults and Children |
|
May be given once daily with evening meal or at bedtime or twice-daily (in the AM and PM). SC inj only into thigh, abdominal wall, or upper arm. <6yrs: not recommended. ≥6yrs: individualize; monitor and adjust as needed. Switching from another basal insulin: dose should be the same on a unit-to-unit basis; may need more insulin detemir when switching from NPH (see literature). Insulin-naive, type 2 diabetics inadequately controlled on oral antidiabetics: initially 0.1–0.2 Units/kg once daily in the evening or 10 Units 1–2 times daily. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Do not mix or dilute with other insulins. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. |
| Adverse Reactions |
|
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema. |
| How Supplied |
Vials (10mL)—1
FlexPen (3mL)—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
